New York Proton Center
New York Proton Center is a single-site proton radiation therapy facility in East Harlem, Manhattan, and the first and only proton therapy center in New York State, treating adult and pediatric cancer patients via pencil beam scanning IMPT under a partnership with Memorial Sloan Kettering, Montefiore, and Mount Sinai.
- Company typePrivate
- Founded2019
- HeadquartersNew City, United States
- Headcount51–100
- GTM typeB2C
- OfferingServices
What New York Proton Center does
New York Proton Center (NYPC) is a single-site, for-profit proton radiation therapy facility located in East Harlem, Manhattan, and the first and only proton therapy center in New York State, opened in 2019. The center was established through a tripartite partnership among Memorial Sloan Kettering Cancer Center, Montefiore Health System, and Mount Sinai Health System, whose radiation oncologists co-staff NYPC and refer their patients there. NYPC treats adult and pediatric solid-tumor cancer patients across 15+ condition categories including brain, breast, head and neck, lung, prostate, pediatric, recurrent, and ocular cancers, drawing patients from the NYC metro area, the broader US, and internationally.
NYPC's core technology is pencil beam scanning (PBS) intensity-modulated proton therapy (IMPT), delivered through a Varian ProBeam system with a 90-ton cyclotron, vacuum beamline, rotating gantry, and fixed-beam rooms. Supporting capabilities include adaptive treatment planning, advanced robotic patient positioning, on-site CT/PET/MRI imaging, and emerging modalities such as FLASH radiotherapy and 5-fraction stereotactic body proton therapy (SBRT). The center reports 7,300+ patients treated since opening, a 97% clinical trial enrollment rate, and a 46.75% recurrent-cancer share that materially exceeds the 11% national average.
NYPC generates revenue by providing proton radiation therapy treatment courses billed primarily through Medicare, Medicaid, and commercial insurance contracts, supplemented by a financial assistance and sliding-fee program. GTM combines institutional partner-hospital referrals, national and international physician referrals (intake turnaround within 48 business hours), direct-to-patient self-referrals via a public consultation line and website, conference presence at PTCOG and NAPT, and a patient alumni network. The center's research collaborations span the Proton Collaborative Group, NRG Oncology, the Children's Oncology Group, and the Proton Therapy Academy. Chairman is Donald Scanlon; CEO is Christopher Panczner; Chief Medical Officer is Dr. Charles B. Simone II.
New York Proton Center firmographics
Firmographics- Name
- New York Proton Center
- Legal name
- New York Proton Center
- Website
- https://nyproton.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- New York Proton Center is a single-site proton radiation therapy facility in East Harlem, Manhattan, and the first and only proton therapy center in New York State, treating adult and pediatric cancer patients via pencil beam scanning IMPT under a partnership with Memorial Sloan Kettering, Montefiore, and Mount Sinai.
- Ownership category
- akta.pro rank
New York Proton Center industry classification
Industry- Product category
- Proton Therapy Services
- NAICS
- Diagnostic Imaging Centers (621512)
- SIC
- Services-Specialty Outpatient Facilities, Nec (8093)
- akta.pro primary industry
- Radiation Oncology (HLAKAFAC)
- akta.pro secondary industries
- Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology) (HLAFAKAB)
Keywords
Where New York Proton Center is headquartered
LocationHeadquarters
- HQ city
- New City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
New York Proton Center business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Proton Therapy Treatment Services: NYPC generates revenue by providing proton radiation therapy treatment services to patients with cancer. Treatment is billed per patient per course of care. The center participates with Medicare, Medicaid, and many private insurance providers. For uninsured or underinsured patients, a financial assistance policy offers sliding fee discounts based on income and family size. The majority of revenue is derived from third-party payer contracts (insurance reimbursement).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Pay-as-you-go | Insurance-covered proton therapy (Medicare, Medicaid, commercial insurers) |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels12 records
New York Proton Center product offering
Product offeringCore offering
New York Proton Center delivers outpatient proton radiation therapy services using Pencil Beam Scanning (IMPT), the most advanced form of proton therapy, targeting solid tumor cancers with sub-millimeter precision while sparing healthy tissues. The center treats both adult and pediatric cancer patients across multiple tumor types and supports an active clinical trials research program enrolling nearly all patients.
Product overview
New York Proton Center is a single-site proton therapy center offering advanced radiation oncology services, specifically pencil beam scanning and intensity-modulated proton therapy (IMPT) as its primary treatment modality. The center provides 5-fraction SBRT proton therapy for accelerated prostate cancer treatment, FLASH ultra-high dose rate therapy, and specialized reirradiation for recurrent tumors. Supporting services include the FollowMyHealth patient portal for health information access, the Forward Together support registry for non-clinical patient assistance, an immersive virtual tour, and an extensive clinical trials program with 97% patient enrollment. The center is the first and only proton therapy provider in New York State, operating as a partnership among Memorial Sloan Kettering Cancer Center, Montefiore Health System, and Mount Sinai Health System.
Differentiator
Problem solved
Functional benefit
Products and services
- Pencil Beam Scanning / Intensity-Modulated Proton Therapy (IMPT) The most advanced form of proton therapy delivered at NYPC; uses an extremely narrow proton beam to paint radiation dose spot-by-spot, layer-by-layer in 3D to match the exact shape and size of the tumor while sparing surrounding healthy tissue. Used for all NYPC adult and pediatric cancer patients.
- 5-Fraction Stereotactic Body Proton Therapy (SBRT) for Prostate Cancer An accelerated proton therapy treatment course for prostate cancer delivering treatment in just 5 sessions over one to two weeks, compared to traditional radiation therapy which typically takes five to eight weeks. Designed for prostate cancer patients seeking shorter treatment duration.
- FLASH Proton Therapy Ultra-high dose rate proton therapy treatment designed to spare healthy tissues while effectively delivering radiation to tumors. Under research and presentation at NYPC as an emerging modality.
- Proton Reirradiation for Recurrent Cancer Specialized proton therapy treatment for patients with recurrent tumors who have previously received radiation, leveraging the Bragg peak property of protons to deposit minimal radiation in nearby organs and avoid exit dose, enabling safer re-treatment than conventional photon radiation.
Quantifiable outcome
- 7,300+ patients treated at NYPC since opening in 2019
- +7 more outcomes
Companies that use New York Proton Center
Customer profileNamed customers19 records
Segments4 records
Ideal customer profiles3 records
New York Proton Center technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature7 records
New York Proton Center partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core / flagship and minor / support.
- Memorial Sloan Kettering Cancer Centercore / flagshipNYPC was created through a partnership with Memorial Sloan Kettering Cancer Center (MSK), one of the world's leading cancer centers. MSK radiation oncologists staff NYPC, treat their patients there, and contribute to research and clinical trials. MSK physicians include Dr. J. Isabelle Choi (Director of Research at NYPC), Dr. Christopher Crane, Dr. Nancy Lee, Dr. Christopher Jackson, Dr. Suzanne Wolden, Dr. Josh Yamada, Dr. Matthew McMillan, Dr. Narek Shaverdian, Dr. Christopher Barker, and Dr. Kaled Alektiar, among others.
- Montefiore Health Systemcore / flagshipNYPC was created through a partnership with Montefiore Health System, a premier academic medical center in the Bronx, New York. Montefiore radiation oncologists staff NYPC and treat their patients there, contributing to clinical research. Montefiore physicians at NYPC include Dr. Madhur Garg (Clinical Director of Radiation Oncology and Director of Montefiore-Einstein's Proton Therapy Program), Dr. Jana Fox, Dr. Rafi Kabarriti, Dr. Keyur Mehta, Dr. Nitin Ohri, Dr. Karin Skalina, and Dr. Justin Tang.
- Mount Sinai Health Systemcore / flagshipNYPC was created through a partnership with Mount Sinai Health System, an integrated healthcare system internationally acclaimed for excellence in research, patient care, and education. Mount Sinai radiation oncologists staff NYPC and treat their patients there. Mount Sinai physicians at NYPC include Dr. Richard Bakst, Dr. Julie Bloom, Dr. Daniel Dickstein, Dr. Stanislav Lazarev, Dr. Deborah Marshall, Dr. Anthony Nehlsen, and Dr. Kunal Sindhu.
- The WiTT Group Inc.minor / supportNYPC partnered with The WiTT Group Inc. to offer patients the Forward Together Support Registry — a free online platform where patients can request assistance with non-clinical needs (transportation, food, housing, co-pays, babysitting, dog walking, etc.) from family, friends, and anonymous donors. This partnership enhances the patient experience and generates community support.
- Varian Medical Systemscore / flagshipNYPC uses Varian's ProBeam proton therapy system, which includes the cyclotron, beamlines, rotating gantries, and fixed-beam treatment rooms. The ProBeam system enables pencil beam scanning (IMPT), NYPC's primary treatment modality. This is a critical technology infrastructure partnership underpinning all of NYPC's clinical operations.
- Proton Therapy Academycore / flagshipNYPC is part of the Proton Therapy Academy network, one of nine leading cancer treatment institutions from the United States, Europe, and Asia that lead the way in proton therapy education and training. This network enables NYPC to contribute to and benefit from shared educational resources, training programs, and best practices in proton therapy.
- National Association for Proton Therapy (NAPT)core / flagshipNYPC is a member of NAPT's 54-member network of leading U.S. cancer centers. NYPC physicians participate in NAPT conferences and educational initiatives including the 'Let's Talk Protons' awareness campaign. NAPT is the primary professional organization advancing proton therapy in the United States.
- Proton Collaborative Group (PCG)core / flagshipNYPC participates in the Proton Collaborative Group (PCG) registry and clinical trials, contributing to and benefiting from multi-center proton therapy research. PCG trials include PCG BRE 007-12 (Phase II partial breast irradiation) and PCG BRE 009-23 (Phase III COMPRO trial for breast cancer nodal irradiation).
- NRG Oncologycore / flagshipNYPC participates in NRG Oncology clinical trials, including NRG-BN014 (proton craniospinal irradiation), NRG GI006 (proton vs. IMRT for esophageal cancer), NRG-HN014 (neoadjuvant immunotherapy for cutaneous squamous cell carcinoma), NRG LU008 (SBRT + chemoradiation for NSCLC), and others. NRG Oncology is a National Cancer Institute-funded research organization.
- Children's Oncology Group (COG)core / flagshipNYPC participates in COG clinical trials for pediatric cancers, including COG ACNS2021 (CNS germ cell tumors), COG-ARST2032 (rhabdomyosarcoma), COG-AHOD2131 (Hodgkin lymphoma), COG-ACNS2321 (CNS germinomas), COG-ACNS1821 (DIPG and HGG), COG-ACNS2031 (medulloblastoma ototoxicity reduction), and others. COG is the world's largest organization devoted to childhood and adolescent cancer research.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
New York Proton Center competitors and assessment
Company assessmentDirect peers
- University of Florida Health Proton Therapy Institute: A high-volume standalone proton center in Jacksonville. Comparable as a dedicated, non-hospital proton facility operating multiple treatment rooms and a large clinical research portfolio.
- Emory Proton Therapy Center: Mid-South regional proton center affiliated with Emory/Winship. Comparable multi-room proton facility serving a major metro and complex cancer cases including pediatric.
- MD Anderson Proton Therapy Center: Operates one of the largest and longest-running proton therapy programs in the U.S. within MD Anderson Cancer Center. Directly comparable as a multi-gantry academic proton center treating complex adult and pediatric cancers.
- Northwestern Medicine Chicago Proton Center: Academic medical center-affiliated proton program in a major U.S. metro. Directly comparable in patient mix, payer mix, and partnership-style operating model to NYPC.
- Massachusetts General Hospital — Burr Proton Therapy Center: Affiliated with Harvard, the Burr Center is a leading U.S. proton facility offering pencil beam scanning across a broad set of indications. Closest direct analogue in terms of academic-medical-center affiliation and case mix.
- Seattle Cancer Care Alliance Proton Therapy: Pacific Northwest academic proton program affiliated with Fred Hutch/UW Medicine. Comparable in scale, case mix, and clinical research intensity.
- Mayo Clinic Proton Beam Therapy Program: Multi-site proton offering at Mayo (Rochester and Arizona campuses). Comparable as a destination cancer program with strong clinical trial integration and complex case mix.
- Penn Medicine — Roberts Proton Therapy Center: University of Pennsylvania-affiliated proton center in Philadelphia offering IMPT and FLASH research; comparable as a Northeast U.S. academic proton program with a similar referral base and case complexity.
- Johns Hopkins — Sibley Memorial Hospital Proton Center: Northeast academic proton program with strong pediatric and CNS focus. Comparable as a multi-room IMPT facility embedded in an academic cancer program.
Broad incumbents
- Varian Medical Systems (Siemens Healthineers): Manufacturer of the ProBeam system NYPC operates; also a broader oncology solutions incumbent. Comparable as the dominant technology supplier underpinning U.S. proton centers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
New York Proton Center social profiles
Digital presenceNew York Proton Center financial estimates
Financial estimateRevenue estimate
Valuation estimate
New York Proton Center leadership team
Management profileNumber of profiles
Profiles14 records
New York Proton Center funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
New York Proton Center M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about New York Proton Center
What does New York Proton Center do?
New York Proton Center delivers outpatient proton radiation therapy services using Pencil Beam Scanning (IMPT), the most advanced form of proton therapy, targeting solid tumor cancers with sub-millimeter precision while sparing healthy tissues. The center treats both adult and pediatric cancer patients across multiple tumor types and supports an active clinical trials research program enrolling nearly all patients.
Is New York Proton Center a public or private company?
New York Proton Center is a private company. It is classified as corporate owned and is currently operating.
When was New York Proton Center founded?
New York Proton Center was founded in 2019. It employs 51 to 100 people.
Where is New York Proton Center based?
New York Proton Center is headquartered in New City, United States, in the North America region.
How does New York Proton Center make money?
One revenue line is on record: proton Therapy Treatment Services.
Who are New York Proton Center's main competitors?
Direct peers on record are University of Florida Health Proton Therapy Institute, Emory Proton Therapy Center, MD Anderson Proton Therapy Center, Northwestern Medicine Chicago Proton Center, Massachusetts General Hospital — Burr Proton Therapy Center, Seattle Cancer Care Alliance Proton Therapy, Mayo Clinic Proton Beam Therapy Program, Penn Medicine — Roberts Proton Therapy Center and Johns Hopkins — Sibley Memorial Hospital Proton Center. Varian Medical Systems (Siemens Healthineers) is listed as a broad incumbent.
Does New York Proton Center have an API?
No public API is recorded for New York Proton Center.
What industry is New York Proton Center in?
New York Proton Center's product category is Proton Therapy Services. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology, with a secondary code of HLAFABAI, Ambulatory Oncology Centers (Outpatient Chemo/Radiation). Its NAICS code is 621512 and its SIC code is 8093.